The rest of this story is for members
The rest is for members
The story continues: the full timeline, the transaction ranges, and the names the forms carry.
Premium comes through the Telegram channel. Already have a code? Sign in to activate it.
Premium
SVRA
In-depth analysis ahead of drug approval for a rare disease
The company is developing a drug for a rare lung disease with a potential market of $1.1 billion, and is expected to receive approval in November.
Other Stories
The weekly SpyStocks magazine: a comprehensive market summary
PremiumMarket Overview1d ago2 min read
Bank of America: special report on Penguin Solutions, $100 target
PremiumAnalystsPENG3d ago2 min read
Unusual move at LB Pharmaceuticals: two analysts initiate coverage with a buy recommendation
PremiumAnalystsLBRX3d ago3 min read